BioScrip Inc. (NASDAQ:BIOS)’s share price was down 5% during mid-day trading on Tuesday . The stock traded as low as $2.45 and last traded at $2.45, with a volume of 422,135 shares trading hands. The stock had previously closed at $2.58.

Separately, Zacks Investment Research downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a research note on Wednesday, May 11th.

The firm’s market capitalization is $178.83 million. The stock’s 50-day moving average is $2.60 and its 200-day moving average is $2.34.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.05. The firm had revenue of $238.50 million for the quarter, compared to analysts’ expectations of $232.38 million. The business’s revenue was down 2.4% on a year-over-year basis. During the same period last year, the firm posted ($0.17) EPS. On average, analysts forecast that BioScrip Inc. will post ($0.20) EPS for the current fiscal year.

In other BioScrip news, Director Coliseum Capital Management, L acquired 4,200,000 shares of the stock in a transaction dated Wednesday, June 22nd. The stock was purchased at an average cost of $2.00 per share, for a total transaction of $8,400,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David W. Golding acquired 12,500 shares of the stock in a transaction dated Friday, June 17th. The stock was acquired at an average price of $2.48 per share, with a total value of $31,000.00. Following the completion of the acquisition, the director now owns 42,500 shares in the company, valued at approximately $105,400. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in BioScrip stock. Diamond Hill Capital Management Inc. raised its position in BioScrip Inc. (NASDAQ:BIOS) by 2.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,055,476 shares of the company’s stock after buying an additional 74,757 shares during the period. Diamond Hill Capital Management Inc. owned about 4.44% of BioScrip worth $5,347,000 at the end of the most recent quarter.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.